{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:18:25Z","timestamp":1792005505707,"version":"4.4.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41380-025-03413-2","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:28:54Z","timestamp":1765805334000},"page":"1156-1166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Potential beneficial effects of PD-1\/PD-L1 blockade in Alzheimer\u2019s disease: a systematic review and meta-analysis of preclinical and clinical studies"],"prefix":"10.1038","volume":"31","author":[{"given":"Jiyoung","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heonyoung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8267-9453","authenticated-orcid":false,"given":"Yun Mi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6451-1542","authenticated-orcid":false,"given":"Heejung","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"3413_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-009-0532-1","volume":"118","author":"C Duyckaerts","year":"2009","unstructured":"Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118:5\u201336.","journal-title":"Acta Neuropathol"},{"key":"3413_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer\u2019s disease. Nat Rev Dis Primers. 2015;1:15056.","journal-title":"Nat Rev Dis Primers"},{"key":"3413_CR3","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1523\/JNEUROSCI.5098-09.2010","volume":"30","author":"I Allaman","year":"2010","unstructured":"Allaman I, Gavillet M, B\u00e9langer M, Laroche T, Viertl D, Lashuel HA, et al. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci. 2010;30:3326\u201338.","journal-title":"J Neurosci"},{"key":"3413_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neures.2017.11.012","volume":"126","author":"H Chun","year":"2018","unstructured":"Chun H, Lee CJ. Reactive astrocytes in Alzheimer\u2019s disease: a double-edged sword. Neurosci Res. 2018;126:44\u201352.","journal-title":"Neurosci Res"},{"key":"3413_CR5","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1016\/j.neurobiolaging.2014.06.004","volume":"35","author":"M Orre","year":"2014","unstructured":"Orre M, Kamphuis W, Osborn LM, Jansen AHP, Kooijman L, Bossers K, et al. Isolation of glia from Alzheimer\u2019s mice reveals inflammation and dysfunction. Neurobiol Aging. 2014;35:2746\u201360.","journal-title":"Neurobiol Aging"},{"key":"3413_CR6","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, et al. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2023;29:1775\u201381.","journal-title":"Nat Med"},{"key":"3413_CR7","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41593-020-00735-y","volume":"23","author":"H Chun","year":"2020","unstructured":"Chun H, Im H, Kang YJ, Kim Y, Shin JH, Won W, et al. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer\u2019s disease via H(2)O(2)(-) production. Nat Neurosci. 2020;23:1555\u201366.","journal-title":"Nat Neurosci"},{"key":"3413_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81705-7","volume":"11","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, M\u00e4larstig AN, Stomrud E, Hansson O, Mattsson-Carlgren N. Accelerated inflammatory aging in Alzheimer\u2019s disease and its relation to amyloid, tau, and cognition. Sci Rep. 2021;11:1965.","journal-title":"Sci Rep"},{"key":"3413_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrn2194","volume":"8","author":"C Ballatore","year":"2007","unstructured":"Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders. Nat Rev Neurosci. 2007;8:663\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"3413_CR10","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41593-023-01415-3","volume":"26","author":"M Jorfi","year":"2023","unstructured":"Jorfi M, Park J, Hall CK, Lin C-CJ, Chen M, von Maydell D, et al. Infiltrating CD8\u2009+\u2009T cells exacerbate Alzheimer\u2019s disease pathology in a 3D human neuroimmune axis model. Nat Neurosci. 2023;26:1489\u2013504.","journal-title":"Nat Neurosci"},{"key":"3413_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01530-z","volume":"11","author":"C Mu\u00f1oz-Castro","year":"2023","unstructured":"Mu\u00f1oz-Castro C, Mejias-Ortega M, Sanchez-Mejias E, Navarro V, Trujillo-Estrada L, Jimenez S, et al. Monocyte-derived cells invade brain parenchyma and amyloid plaques in human Alzheimer\u2019s disease hippocampus. Acta Neuropathologica Commun. 2023;11:31.","journal-title":"Acta Neuropathologica Commun"},{"key":"3413_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41586-023-05788-0","volume":"615","author":"X Chen","year":"2023","unstructured":"Chen X, Firulyova M, Manis M, Herz J, Smirnov I, Aladyeva E, et al. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature. 2023;615:668\u201377.","journal-title":"Nature"},{"key":"3413_CR13","doi-asserted-by":"publisher","first-page":"69347","DOI":"10.18632\/oncotarget.12469","volume":"7","author":"H Baek","year":"2016","unstructured":"Baek H, Ye M, Kang GH, Lee C, Lee G, Choi DB, et al. Neuroprotective effects of CD4\u2009+\u2009CD25\u2009+\u2009Foxp3\u2009+\u2009regulatory T cells in a 3xTg-AD Alzheimer\u2019s disease model. Oncotarget. 2016;7:69347\u201357.","journal-title":"Oncotarget"},{"key":"3413_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s43587-021-00149-w","volume":"2","author":"R Dvir-Szternfeld","year":"2022","unstructured":"Dvir-Szternfeld R, Castellani G, Arad M, Cahalon L, Colaiuta SP, Keren-Shaul H, et al. Alzheimer\u2019s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis. Nat Aging. 2022;2:60\u201373.","journal-title":"Nat Aging"},{"key":"3413_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765\u201372.","journal-title":"Int Immunol"},{"key":"3413_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","volume":"7","author":"K Bardhan","year":"2016","unstructured":"Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1\/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550.","journal-title":"Front Immunol"},{"key":"3413_CR17","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/j.neuron.2023.05.022","volume":"111","author":"J Zhao","year":"2023","unstructured":"Zhao J, Bang S, Furutani K, McGinnis A, Jiang C, Roberts A, et al. PD-L1\/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior. Neuron. 2023;111:2709\u201326.e9.","journal-title":"Neuron"},{"key":"3413_CR18","doi-asserted-by":"publisher","first-page":"eaaw6471","DOI":"10.1126\/scitranslmed.aaw6471","volume":"12","author":"Z Wang","year":"2020","unstructured":"Wang Z, Jiang C, He Q, Matsuda M, Han Q, Wang K, et al. Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates. Sci Transl Med. 2020;12:eaaw6471.","journal-title":"Sci Transl Med"},{"key":"3413_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s12264-021-00683-y","volume":"37","author":"J Zhao","year":"2021","unstructured":"Zhao J, Roberts A, Wang Z, Savage J, Ji R-R. Emerging Role of PD-1 in the central nervous system and brain diseases. Neurosci Bull. 2021;37:1188\u2013202.","journal-title":"Neurosci Bull"},{"key":"3413_CR20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/glia.22701","volume":"62","author":"SJ Schachtele","year":"2014","unstructured":"Schachtele SJ, Hu S, Sheng WS, Mutnal MB, Lokensgard JR. Glial cells suppress postencephalitic CD8\u2009+\u2009T lymphocytes through PD\u2010L1. Glia. 2014;62:1582\u201394.","journal-title":"Glia"},{"key":"3413_CR21","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108662","volume":"40","author":"MP Kummer","year":"2021","unstructured":"Kummer MP, Ising C, Kummer C, Sarlus H, Griep A, Vieira\u2010Saecker A, et al. Microglial PD\u20101 stimulation by astrocytic PD\u2010L1 suppresses neuroinflammation and Alzheimer\u2019s disease pathology. EMBO J. 2021;40:e108662.","journal-title":"EMBO J"},{"key":"3413_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40982-8","volume":"14","author":"M Linnerbauer","year":"2023","unstructured":"Linnerbauer M, Beyer T, Nirschl L, Farrenkopf D, L\u00f6\u00dflein L, Vandrey O, et al. PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation. Nat Commun. 2023;14:5555.","journal-title":"Nat Commun"},{"key":"3413_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58674-4","volume":"10","author":"L Sun","year":"2020","unstructured":"Sun L, Zhang L, Yu J, Zhang Y, Pang X, Ma C, et al. Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020;10:2083.","journal-title":"Sci Rep"},{"key":"3413_CR24","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00432-022-04286-6","volume":"149","author":"D Wankhede","year":"2023","unstructured":"Wankhede D, Hofman P, Grover S. PD-1\/PD-L1 inhibitors in treatment-na\u00efve, advanced non-small cell lung cancer patients with\u2009<\u20091% PD-L1 expression: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2023;149:2179\u201389.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3413_CR25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","volume":"36","author":"DJ Vaughn","year":"2018","unstructured":"Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, et al. Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer. J Clin Oncol. 2018;36:1579\u201387.","journal-title":"J Clin Oncol"},{"key":"3413_CR26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","volume":"22","author":"T Andre","year":"2021","unstructured":"Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:665\u201377.","journal-title":"Lancet Oncol"},{"key":"3413_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/JCO.21.00601","volume":"40","author":"A Adenis","year":"2022","unstructured":"Adenis A, Kulkarni AS, Girotto GC, de la Fouchardiere C, Senellart H, van Laarhoven HWM, et al. Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. J Clin Oncol. 2022;40:382\u201391.","journal-title":"J Clin Oncol"},{"key":"3413_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cncr.33317","volume":"127","author":"BY Ryoo","year":"2021","unstructured":"Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, et al. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. Cancer. 2021;127:865\u201374.","journal-title":"Cancer"},{"key":"3413_CR29","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","volume":"18","author":"JR Brahmer","year":"2017","unstructured":"Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. lancet Oncol. 2017;18:1600\u201309.","journal-title":"lancet Oncol"},{"key":"3413_CR30","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.","journal-title":"Bmj"},{"key":"3413_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"3413_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","volume":"178","author":"K Cocks","year":"2023","unstructured":"Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, Oerlemans S, et al. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer. 2023;178:128\u201338.","journal-title":"Eur J Cancer"},{"key":"3413_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139\u201344.","journal-title":"J Clin Oncol"},{"key":"3413_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12959-023-00519-x","volume":"21","author":"J Hahn","year":"2023","unstructured":"Hahn J, Jeon J, Geum MJ, Lee HW, Shin J, Chung WY, et al. Intracoronary versus intravenous glycoprotein IIb\/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis. Thromb J. 2023;21:76.","journal-title":"Thromb J"},{"key":"3413_CR35","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"3413_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.","journal-title":"BMC Med Res Methodol"},{"key":"3413_CR37","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.","journal-title":"Bmj"},{"key":"3413_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.769229","volume":"9","author":"Y Zou","year":"2021","unstructured":"Zou Y, Gan CL, Xin Z, Zhang HT, Zhang Q, Lee TH, et al. Programmed cell death protein 1 blockade reduces glycogen synthase kinase 3\u03b2 activity and tau hyperphosphorylation in alzheimer\u2019s disease mouse models. Front Cell Dev Biol. 2021;9:769229.","journal-title":"Front Cell Dev Biol"},{"key":"3413_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bbi.2020.09.015","volume":"91","author":"Z Xing","year":"2021","unstructured":"Xing Z, Zuo Z, Hu D, Zheng X, Wang X, Yuan L, et al. Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid-\u03b2 accumulation and improves cognition in APP\/PS1 mice. Brain Behav Immun. 2021;91:128\u201341.","journal-title":"Brain Behav Immun"},{"key":"3413_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-021-00458-z","volume":"16","author":"H Ben-Yehuda","year":"2021","unstructured":"Ben-Yehuda H, Arad M, Peralta Ramos JM, Sharon E, Castellani G, Ferrera S, et al. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy. Mol neurodegeneration. 2021;16:1\u201319.","journal-title":"Mol neurodegeneration"},{"key":"3413_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08352-5","volume":"10","author":"N Rosenzweig","year":"2019","unstructured":"Rosenzweig N, Dvir-Szternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P, et al. PD-1\/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat Commun. 2019;10:465.","journal-title":"Nat Commun"},{"key":"3413_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fnagi.2019.00377","volume":"11","author":"Y Lin","year":"2019","unstructured":"Lin Y, Rajamohamedsait HB, Sandusky-Beltran LA, Gamallo-Lana B, Mar A, Sigurdsson EM. Chronic PD-1 checkpoint blockade does not affect cognition or promote tau clearance in a tauopathy mouse model. Front Aging Neurosci. 2019;11:377.","journal-title":"Front Aging Neurosci"},{"key":"3413_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-019-0498-4","volume":"20","author":"F Karl","year":"2019","unstructured":"Karl F, Cola\u00e7o MBN, Schulte A, Sommer C, \u00dc\u00e7eyler N. Affective and cognitive behavior is not altered by chronic constriction injury in B7-H1 deficient and wildtype mice. BMC Neurosci. 2019;20:16.","journal-title":"BMC Neurosci"},{"key":"3413_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nm.4022","volume":"22","author":"K Baruch","year":"2016","unstructured":"Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer\u2019s disease. Nat Med. 2016;22:135\u201337.","journal-title":"Nat Med"},{"key":"3413_CR45","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/glia.23260","volume":"66","author":"M Latta\u2010Mahieu","year":"2018","unstructured":"Latta\u2010Mahieu M, Elmer B, Bretteville A, Wang Y, Lopez\u2010Grancha M, Goniot P, et al. Systemic immune\u2010checkpoint blockade with anti\u2010PD1 antibodies does not alter cerebral amyloid\u2010\u03b2 burden in several amyloid transgenic mouse models. Glia. 2018;66:492\u2013504.","journal-title":"Glia"},{"key":"3413_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fnmol.2017.00219","volume":"10","author":"F Karl","year":"2017","unstructured":"Karl F, Grie\u00dfhammer A, \u00dc\u00e7eyler N, Sommer C. Differential Impact of miR-21 on pain and associated affective and cognitive behavior after spared nerve injury in B7-H1 ko mouse. Front Mol Neurosci. 2017;10:219.","journal-title":"Front Mol Neurosci"},{"key":"3413_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj9672","volume":"16","author":"JM Vinnakota","year":"2024","unstructured":"Vinnakota JM, Adams RC, Athanassopoulos D, Schmidt D, Biavasco F, Z\u00e4hringer A, et al. Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation. Sci Transl Med. 2024;16:eadj9672.","journal-title":"Sci Transl Med"},{"key":"3413_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03255-9","volume":"21","author":"W Rui","year":"2024","unstructured":"Rui W, Wu Y, Yang Y, Xie W, Qin D, Ming J, et al. Myeloid gasdermin D drives early-stage T cell immunity and peripheral inflammation in a mouse model of Alzheimer\u2019s disease. J Neuroinflammation. 2024;21:266.","journal-title":"J Neuroinflammation"},{"key":"3413_CR49","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jtho.2019.01.016","volume":"14","author":"F Barlesi","year":"2019","unstructured":"Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, et al. Health-related quality of life in KEYNOTE-010: a phase II\/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC. J Thorac Oncol. 2019;14:793\u2013801.","journal-title":"J Thorac Oncol"},{"key":"3413_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. lancet Oncol. 2020;21:387\u201397.","journal-title":"lancet Oncol"},{"key":"3413_CR51","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","volume":"18","author":"KJ Harrington","year":"2017","unstructured":"Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. lancet Oncol. 2017;18:1104\u201315.","journal-title":"lancet Oncol"},{"key":"3413_CR52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jnci\/djaa063","volume":"113","author":"KJ Harrington","year":"2021","unstructured":"Harrington KJ, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra LF, Ahn MJ, et al. Quality of Life With Pembrolizumab for Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. J Natl Cancer Inst. 2021;113:171\u201381.","journal-title":"J Natl Cancer Inst"},{"key":"3413_CR53","volume":"4","author":"HR Kim","year":"2023","unstructured":"Kim HR, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, et al. Patient-reported health-related quality of life in KEYNOTE-604: pembrolizumab or placebo added to etoposide and platinum as first-line therapy for extensive-stage SCLC. JTO Clin Res Rep. 2023;4:100572.","journal-title":"JTO Clin Res Rep"},{"key":"3413_CR54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2023.03.015","volume":"186","author":"D Lorusso","year":"2023","unstructured":"Lorusso D, Colombo N, Herraez AC, Santin AD, Colomba E, Miller DS, et al. Health-related quality of life in patients with advanced endometrial cancer treated with lenvatinib plus pembrolizumab or treatment of physician\u2019s choice. Eur J cancer. 2023;186:172\u201384.","journal-title":"Eur J cancer"},{"key":"3413_CR55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1200\/JCO.19.01348","volume":"38","author":"J Mazieres","year":"2020","unstructured":"Mazieres J, Kowalski D, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer. J Clin Oncol. 2020;38:271\u201380.","journal-title":"J Clin Oncol"},{"key":"3413_CR56","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejca.2022.03.016","volume":"174","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Monk BJ, Vergote I, Cristina de Melo A, Kim YM, Lisyanskaya AS, et al. EMPOWER CERVICAL-1: effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. Eur J Cancer. 2022;174:299\u2013309.","journal-title":"Eur J Cancer"},{"key":"3413_CR57","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000535338","volume":"13","author":"S Qin","year":"2024","unstructured":"Qin S, Fang W, Ren Z, Ou S, Lim HY, Zhang F, et al. A Phase 3 Study of pembrolizumab versus placebo for previously treated patients from asia with hepatocellular carcinoma: health-related quality of life analysis from KEYNOTE-394. Liver Cancer. 2024;13:389\u2013400.","journal-title":"Liver Cancer"},{"key":"3413_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105815","volume":"128","author":"D Rischin","year":"2022","unstructured":"Rischin D, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048. Oral Oncol. 2022;128:105815.","journal-title":"Oral Oncol"},{"key":"3413_CR59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","volume":"67","author":"D Schadendorf","year":"2016","unstructured":"Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J cancer. 2016;67:46\u201354.","journal-title":"Eur J cancer"},{"key":"3413_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113393","volume":"195","author":"P Schmid","year":"2023","unstructured":"Schmid P, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, et al. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study. Eur J cancer. 2023;195:113393.","journal-title":"Eur J cancer"},{"key":"3413_CR61","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s10120-021-01200-w","volume":"24","author":"E Van Cutsem","year":"2021","unstructured":"Van Cutsem E, Amonkar M, Fuchs CS, Alsina M, \u00d6zg\u00fcro\u011flu M, Bang YJ, et al. Health-related quality of life in advanced gastric\/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. Gastric cancer. 2021;24:1330\u201340.","journal-title":"Gastric cancer"},{"key":"3413_CR62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.esmoop.2021.100189","volume":"6","author":"E Van Cutsem","year":"2021","unstructured":"Van Cutsem E, Valderrama A, Bang YJ, Fuchs CS, Shitara K, Janjigian YY, et al. Quality of life with first-line pembrolizumab for PD-L1epositive advanced gastric\/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study. ESMO Open. 2021;6:11.","journal-title":"ESMO Open"},{"key":"3413_CR63","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2021004970","volume":"6","author":"PL Zinzani","year":"2022","unstructured":"Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical hodgkin lymphoma. Blood Adv. 2022;6:590\u201399.","journal-title":"Blood Adv"},{"key":"3413_CR64","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/jnci\/djad240","volume":"116","author":"DW Cescon","year":"2024","unstructured":"Cescon DW, Schmid P, Rugo HS, Im SA, Md Yusof M, Gallardo C, et al. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. J Natl Cancer Inst. 2024;116:717\u201327.","journal-title":"J Natl Cancer Inst"},{"key":"3413_CR65","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/jnci\/djae129","volume":"116","author":"R Dent","year":"2024","unstructured":"Dent R, Cort\u00e9s J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Neoadjuvant pembrolizumab plus chemotherapy\/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. J Natl Cancer Inst. 2024;116:1654\u201363.","journal-title":"J Natl Cancer Inst"},{"key":"3413_CR66","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1159\/000537966","volume":"13","author":"RS Finn","year":"2024","unstructured":"Finn RS, Kudo M, Barnes G, Meyer T, Boisserie F, Abdrashitov R, et al. Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study. Liver Cancer. 2024;13:548\u201360.","journal-title":"Liver Cancer"},{"key":"3413_CR67","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","volume":"26","author":"S Gupta","year":"2025","unstructured":"Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, et al. Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2025;26:795\u2013805.","journal-title":"Lancet Oncol"},{"key":"3413_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005484","volume":"35","author":"G Valabrega","year":"2025","unstructured":"Valabrega G, Powell MA, Hietanen S, Miller EM, Novak Z, Holloway R, et al. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient\/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO\/GOG3031\/RUBY trial. Int J Gynecol Cancer. 2025;35:101852.","journal-title":"Int J Gynecol Cancer"},{"key":"3413_CR69","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2025.03.019","volume":"83","author":"C Yoo","year":"2025","unstructured":"Yoo C, Ueno M, Kl\u00fcmpen HJ, Kelley RK, Vogel A, Furuse J, et al. Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. J Hepatol. 2025;83:692\u2013700.","journal-title":"J Hepatol"},{"key":"3413_CR70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-024-00703-1","volume":"19","author":"V Giusti","year":"2024","unstructured":"Giusti V, Kaur G, Giusto E, Civiero L. Brain clearance of protein aggregates: a close-up on astrocytes. Mol Neurodegener. 2024;19:5.","journal-title":"Mol Neurodegener"},{"key":"3413_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13024-016-0098-z","volume":"11","author":"S S\u00f6llvander","year":"2016","unstructured":"S\u00f6llvander S, Nikitidou E, Brolin R, S\u00f6derberg L, Sehlin D, Lannfelt L, et al. Accumulation of amyloid-\u03b2 by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons. Mol Neurodegener. 2016;11:38.","journal-title":"Mol Neurodegener"},{"key":"3413_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03410-w","volume":"22","author":"J Zeng","year":"2025","unstructured":"Zeng J, Indajang J, Pitt D, Lo CH. Lysosomal acidification impairment in astrocyte-mediated neuroinflammation. J Neuroinflammation. 2025;22:72.","journal-title":"J Neuroinflammation"},{"key":"3413_CR73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13024-024-00750-8","volume":"19","author":"T Guo","year":"2024","unstructured":"Guo T, Li A, Sun P, He Z, Cai Y, Lan G, et al. Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer\u2019s disease. Mol Neurodegener. 2024;19:58.","journal-title":"Mol Neurodegener"},{"key":"3413_CR74","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41380-022-01716-2","volume":"27","author":"JP Ferrari-Souza","year":"2022","unstructured":"Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, et al. Astrocyte biomarker signatures of amyloid-\u03b2 and tau pathologies in Alzheimer\u2019s disease. Mol Psychiatry. 2022;27:4781\u201389.","journal-title":"Mol Psychiatry"},{"key":"3413_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0557-6","volume":"6","author":"J Neddens","year":"2018","unstructured":"Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, et al. Phosphorylation of different tau sites during progression of Alzheimer\u2019s disease. Acta Neuropathologica Commun. 2018;6:52.","journal-title":"Acta Neuropathologica Commun"},{"key":"3413_CR76","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1111\/jnc.16106","volume":"168","author":"C Netzahualcoyotzi","year":"2024","unstructured":"Netzahualcoyotzi C, Santill\u00e1n-Cigales JJ, Adalid-Peralta LV, Velasco I. Infiltration of immune cells to the brain and its relation to the pathogenesis of Alzheimer\u2019s and parkinson\u2019s diseases. J Neurochem. 2024;168:2316\u201334.","journal-title":"J Neurochem"},{"key":"3413_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1616939","volume":"16","author":"Y Cao","year":"2025","unstructured":"Cao Y, Tang K, Ma P, Zhang R, Yang Y, Li T, et al. The role of peripheral innate immune cells in Alzheimer\u2019s disease progression. Front Immunol. 2025;16:1616939.","journal-title":"Front Immunol"},{"key":"3413_CR78","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21:1346\u201358.","journal-title":"Nat Immunol"},{"key":"3413_CR79","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u201399.","journal-title":"Nature"},{"key":"3413_CR80","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.neuron.2006.01.022","volume":"49","author":"AR Simard","year":"2006","unstructured":"Simard AR, Soulet D, Gowing G, Julien J-P, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer\u2019s disease. Neuron. 2006;49:489\u2013502.","journal-title":"Neuron"},{"key":"3413_CR81","doi-asserted-by":"publisher","first-page":"e152565","DOI":"10.1172\/JCI152565","volume":"132","author":"P Yan","year":"2022","unstructured":"Yan P, Kim K-W, Xiao Q, Ma X, Czerniewski LR, Liu H, et al. Peripheral monocyte\u2013derived cells counter amyloid plaque pathogenesis in a mouse model of Alzheimer\u2019s disease. J Clin Investigation. 2022;132:e152565.","journal-title":"J Clin Investigation"},{"key":"3413_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01447-z","volume":"10","author":"A Faridar","year":"2022","unstructured":"Faridar A, Vasquez M, Thome AD, Yin Z, Xuan H, Wang JH, et al. Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer\u2019s disease. Acta Neuropathologica Commun. 2022;10:144.","journal-title":"Acta Neuropathologica Commun"},{"key":"3413_CR83","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-018-0824-5","volume":"565","author":"M Ito","year":"2019","unstructured":"Ito M, Komai K, Mise-Omata S, Iizuka-Koga M, Noguchi Y, Kondo T, et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature. 2019;565:246\u201350.","journal-title":"Nature"},{"key":"3413_CR84","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13024-017-0222-8","volume":"12","author":"A Sommer","year":"2017","unstructured":"Sommer A, Winner B, Prots I. The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases. Mol Neurodegener. 2017;12:78.","journal-title":"Mol Neurodegener"},{"key":"3413_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155653","volume":"148","author":"K Oppegaard","year":"2021","unstructured":"Oppegaard K, Harris CS, Shin J, Paul SM, Cooper BA, Chan A, et al. Cancer-related cognitive impairment is associated with perturbations in inflammatory pathways. Cytokine. 2021;148:155653.","journal-title":"Cytokine"},{"key":"3413_CR86","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/09540261.2013.864260","volume":"26","author":"MC Janelsins","year":"2014","unstructured":"Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26:102\u201313.","journal-title":"Int Rev Psychiatry"},{"key":"3413_CR87","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1055\/s-0035-1555115","volume":"36","author":"DL Murman","year":"2015","unstructured":"Murman DL. The Impact of age on cognition. Semin Hear. 2015;36:111\u201321.","journal-title":"Semin Hear"},{"key":"3413_CR88","doi-asserted-by":"publisher","first-page":"370","DOI":"10.21873\/cdp.10226","volume":"3","author":"T Inamoto","year":"2023","unstructured":"Inamoto T, Sato R, Matsushita Y, Uchimoto T, Nakamura KO, Komura K, et al. Optimal time point for evaluation of response to pembrolizumab treatment in japanese patients with metastatic urothelial carcinoma. Cancer Diagn Progn. 2023;3:370\u201376.","journal-title":"Cancer Diagn Progn"},{"key":"3413_CR89","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.21037\/atm.2019.08.91","volume":"7","author":"P Bironzo","year":"2019","unstructured":"Bironzo P, Passiglia F, Novello S. Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure? Ann Transl Med. 2019;7:S212.","journal-title":"Ann Transl Med"},{"key":"3413_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01259-0","volume":"21","author":"P Gebert","year":"2021","unstructured":"Gebert P, Schindel D, Frick J, Schenk L, Grittner U. Characteristics and patient-reported outcomes associated with dropout in severely affected oncological patients: an exploratory study. BMC Med Res Methodol. 2021;21:77.","journal-title":"BMC Med Res Methodol"},{"key":"3413_CR91","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","volume":"13","author":"JB Stone","year":"2016","unstructured":"Stone JB, DeAngelis LM. Cancer-treatment-induced neurotoxicity-focus on newer treatments. Nat Rev Clin Oncol. 2016;13:92\u2013105.","journal-title":"Nat Rev Clin Oncol"},{"key":"3413_CR92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"3413_CR93","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"3413_CR94","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the alzheimer\u2019s association research roundtable workgroup. Alzheimers Dement. 2011;7:367\u201385.","journal-title":"Alzheimers Dement"},{"key":"3413_CR95","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"key":"3413_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","volume":"42","author":"Q Wu","year":"2021","unstructured":"Wu Q, Jiang L, Li SC, He QJ, Yang B, Cao J. Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021;42:1\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"3413_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03590-4","volume":"12","author":"CH Lu","year":"2022","unstructured":"Lu CH, Chung WM, Tsai CH, Cheng JC, Hsu KC, Tzeng HE. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l\/PD-L1 interaction. Sci Rep. 2022;12:303.","journal-title":"Sci Rep"},{"key":"3413_CR98","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40259-018-0303-4","volume":"32","author":"PG Sasikumar","year":"2018","unstructured":"Sasikumar PG, Ramachandra M. Small-molecule immune checkpoint inhibitors targeting PD-1\/PD-L1 and other emerging checkpoint pathways. BioDrugs. 2018;32:481\u201397.","journal-title":"BioDrugs"},{"key":"3413_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06553-5","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang X, Wang W, Ji T. Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma. Cell Death Dis. 2024;15:186.","journal-title":"Cell Death Dis"},{"key":"3413_CR100","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13046-025-03442-3","volume":"44","author":"OV Ifejeokwu","year":"2025","unstructured":"Ifejeokwu OV, Do AH, El Khatib SM, Ho NN, Zavala A, Othy S, et al. Immune checkpoint inhibition perturbs neuro-immune homeostasis and impairs cognitive function. J Exp Clin Cancer Res. 2025;44:183.","journal-title":"J Exp Clin Cancer Res"},{"key":"3413_CR101","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s41687-024-00719-7","volume":"8","author":"MJ Pilz","year":"2024","unstructured":"Pilz MJ, Loth FLC, Nolte S, Thurner AMM, Gamper EM, Anota A, et al. General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population. J Patient Rep Outcomes. 2024;8:48.","journal-title":"J Patient Rep Outcomes"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03413-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:02:41Z","timestamp":1768849361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03413-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3413"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03413-2","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"7 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing intrest"}}]}}